Financial Survey: KalVista Pharmaceuticals (KALV) & Its Competitors

KalVista Pharmaceuticals (NASDAQ: KALV) is one of 48 public companies in the “Biopharmaceuticals” industry, but how does it contrast to its peers? We will compare KalVista Pharmaceuticals to similar businesses based on the strength of its dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

Analyst Ratings

This is a summary of recent recommendations for KalVista Pharmaceuticals and its peers, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
KalVista Pharmaceuticals 0 0 1 0 3.00
KalVista Pharmaceuticals Competitors 144 807 1786 60 2.63

KalVista Pharmaceuticals presently has a consensus target price of $27.00, indicating a potential upside of 164.45%. As a group, “Biopharmaceuticals” companies have a potential upside of 7.96%. Given KalVista Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe KalVista Pharmaceuticals is more favorable than its peers.


This table compares KalVista Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
KalVista Pharmaceuticals -1,379.58% -70.20% -63.10%
KalVista Pharmaceuticals Competitors -13,486.12% -54.03% -24.46%

Valuation and Earnings

This table compares KalVista Pharmaceuticals and its peers top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
KalVista Pharmaceuticals $1.50 million -$18.60 million -4.18
KalVista Pharmaceuticals Competitors $584.27 million $101.79 million 62.07

KalVista Pharmaceuticals’ peers have higher revenue and earnings than KalVista Pharmaceuticals. KalVista Pharmaceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Insider & Institutional Ownership

68.6% of KalVista Pharmaceuticals shares are held by institutional investors. Comparatively, 42.7% of shares of all “Biopharmaceuticals” companies are held by institutional investors. 49.1% of KalVista Pharmaceuticals shares are held by company insiders. Comparatively, 15.4% of shares of all “Biopharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc., formerly Carbylan Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME). The Company is developing a plasma kallikrein inhibitor, which is administered directly into the eye. The Company is engaged in advancing several product candidates developed from its portfolio into early clinical trials. The Company is progressing additional oral candidates towards regulatory preclinical studies. The Company’s HAE product candidate, KVD818, is an inhibitor of plasma kallikrein. The Company has initiated clinical testing of KVD818 in a Phase I clinical trial. It has completed an open-label single ascending dose Phase I trial in DME patients with KVD001.

Receive News & Ratings for KalVista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KalVista Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply